PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives
Share this article Share this article PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. "This year we are focused on transforming PYC Therapeutics into a U.S.-based, clinical-stage biotechnology company, including ...
Source: prnewswire.com